Consun Pharmaceutical Group Limited (HKG:1681)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
15.97
-0.14 (-0.87%)
Apr 29, 2026, 10:34 AM HKT
67.75%
Market Cap 13.56B
Revenue (ttm) 3.80B
Net Income (ttm) 1.20B
Shares Out 841.55M
EPS (ttm) 1.40
PE Ratio 11.49
Forward PE 9.55
Dividend 0.80 (5.09%)
Ex-Dividend Date Jun 9, 2026
Volume 181,000
Average Volume 1,580,103
Open 15.74
Previous Close 16.11
Day's Range 15.74 - 16.11
52-Week Range 9.23 - 19.49
Beta 0.61
RSI 44.67
Earnings Date Aug 20, 2026

About HKG:1681

Consun Pharmaceutical Group Limited researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People’s Republic of China. It operates in two segments, Consun Pharmaceutical and Yulin Pharmaceutical. The company offers uremic clearance granule to treat chronic kidney diseases; Yishen Huashi particles for proteinuria; TCM to treat diabetic kidney disease; Gadopentetate Dimeglumine injections for nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function ass... [Read more]

Sector Healthcare
Founded 1997
Employees 3,115
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 1681
Full Company Profile

Financial Performance

In 2025, HKG:1681's revenue was 3.42 billion, an increase of 15.17% compared to the previous year's 2.97 billion. Earnings were 1.08 billion, an increase of 18.41%.

Financial numbers in CNY Financial Statements

News

There is no news available yet.